<DOC>
	<DOCNO>NCT02803918</DOCNO>
	<brief_summary>Primary Objective : To demonstrate safety 14-day repeat lixisenatide dos 3 ascend dos compare placebo pediatric patient T2DM . Secondary Objectives : - To evaluate plasma concentration lixisenatide repeat dos ( 3 ascend dos ) pharmacokinetic parameter repeat lixisenatide dos pediatric patient T2DM . - To evaluate change baseline fast post-prandial plasma glucose concentration standardize meal test 3 ascending repeat dos lixisenatide comparison placebo .</brief_summary>
	<brief_title>A Study Safety , Pharmacokinetics Pharmacodynamics Lixisenatide Pediatric Patients With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>The total study duration 10 week include 6-week treatment period dose escalation every 2 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Inclusion criterion : Male female patient age ≥10 &lt; 18 year old ( least 4 patient 16 year old ) . Body mass index ( BMI ) &gt; 85th percentile age gender ; BMI ≤50 kg/m^2 . Male female patient document T2DM insufficiently control metformin ≥1000 mg/day ( maximum tolerate dose accord Investigator 's judgment ) stable dose regimen 8 week prior randomization and/or basal insulin stable dose ( ±20 % ) regimen 8 week prior randomization . Glycated hemoglobin ( HbA1c ) &gt; 6.5 % ≤11 % screening . Exclusion criterion : If female , ongoing pregnancy ( define positive serum pregnancy test ) , breastfeed . Sexually active postmenarchal female patient agree use adequate highly effective method contraception throughout study duration accord local regulation ( ie , hormonal contraception , condom , etc. ) . Diabetes T2DM . Fasting plasma glucose &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) screening . Use oral injectable antidiabetic hypoglycemic agent metformin basal insulin ( eg , alpha glucosidase inhibitor , glucagonlike peptide ( GLP1 ) receptor agonist , dipeptidyl peptidaseIV ( DPPIV ) inhibitor , shortacting insulin etc . ) within 1 month prior screen visit . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>